Can Blocking the Orexin System Enhance Sleep's Benefits to Therapeutic Exposure for PTSD?

Trial Profile

Can Blocking the Orexin System Enhance Sleep's Benefits to Therapeutic Exposure for PTSD?

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2018

At a glance

  • Drugs Suvorexant (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2018 Planned number of patients changed from 145 to 140.
    • 25 Apr 2017 Planned End Date changed from 1 Mar 2019 to 31 Mar 2021.
    • 25 Apr 2017 Planned primary completion date changed from 1 Mar 2019 to 31 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top